mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Tuberous sclerosis is a genetic disorder affecting multiple organs.
• The mammalian target of rapamycin (mTOR) pathway plays a crucial role in cell growth and proliferation.
• Understanding the mTOR pathway's connection to tuberous sclerosis genes was a key research focus.

Purpose of the Study:

• To review the discovery and characterization of the mTOR pathway in relation to tuberous sclerosis.
• To summarize the clinical development and regulatory approval of mTOR inhibitors for tuberous sclerosis manifestations.
• To discuss the practical application of mTOR inhibitors in improving patient outcomes.

Main Methods:

• Experiments involving Drosophila melanogaster to identify the mTOR pathway.
• Analysis of the relationship between mTOR and tuberous sclerosis-related genes.
• Review of clinical research data on mTOR inhibitor efficacy and safety.

Main Results:

• Identification of the mTOR protein kinase, its pathway, and its link to tuberous sclerosis genes (1993-2003).
• Regulatory approval of mTOR inhibitors for four distinct tuberous sclerosis manifestations: giant cell astrocytoma, angiomyolipoma, lymphangioleiomyomatosis, and epilepsy.
• Demonstrated improvement in patient lives through the use of mTOR inhibitors.

Conclusions:

• The discovery of the mTOR pathway has led to targeted therapies for tuberous sclerosis.
• mTOR inhibitors represent a significant advancement in managing various manifestations of tuberous sclerosis.
• Continued research and application of mTOR inhibitors offer hope for improved quality of life for patients.